

## Subject Index

Numbers refer only to Abstract-No.

- ACA, 323  
ACA and sepsis, 210  
ACA in autoimmune disease, 215  
ACAD, 187  
ACV prevalence, 105  
AMI and fibrinopeptide A, 218  
AMI in young people, 354  
APA in AMI, 354  
APA in Sneddon's syndrome, 332  
APA in infertile women, 322  
APA study, 331  
APC, 9, 93  
APC and thrombophilia, 157  
APC quantification, 214, 219  
APC resistance, 213, 219, 219, 307  
APC resistance and thrombophilia, 146  
APC resistance inheritance, 9  
APC resistance prevalence, 142  
APC resistance, inherited, 143  
APC resistance, methods for, 141  
APC resistance: significance, 152  
APC resistance and OC, 144  
APC response in plasma, 161  
APC test, 9  
APTT quality control, 387  
APTT standardisation, 87  
ATIII and bladder carcinoma, 301  
ATIII in sepsis, 309  
Acenocoumarol, 277  
Activated Protein C, 214  
Activated protein C resistance, 9, 93  
Acute Limb ischaemia, 49, 230  
Acute cerebrovascular disease, 32  
Acute coronary syndrome, 2  
Acute limb ischaemia, 108, 265  
Age related risk factors, 122  
Age risk factors, 41, 107  
Aging and atherosclerosis, 42  
Aging and erythrocyte membrane, 124  
Aging and hypertension, 126  
Aging and lipoprotein(a), 125  
Alfa2-AP, 360  
Ambulatory follow up, 371  
Anaesthesia general, 384  
Anaesthesia, epidural, 386  
Anaesthesia, regional, 384  
Angioplastia, 342  
Angioplasty, 6, 185  
Angioplasty in AMI, 12  
Anticardiolipin antibodies, 138  
Anticoagulant effect of drugs, 24  
Anticoagulant therapy, bleeding, 264  
Anticoagulant therapy, long term, 344  
Anticoagulant activity and pregnancy, 303  
Antipeptide antibodies, 321  
Antiphospholipid antibodies, 51, 53, 56, 225, 322  
Antiphospholipid antibodies, youth, 137  
Antiphospholipid autoantibodies, 333  
Antiphospholipid experimental model, 57  
Antiphospholipid syndrom, 55  
Antiplatelet activity, 357  
Antiplatelet agents, 145  
Antiplatelet drugs, 23  
Antiplatelet medication, 84  
Antiplatelet therapy, 129  
Antithrombin deficiency, hereditary, 139  
Antithrombotic activity, 5  
Antithrombotic compounds, new, 284  
Antithrombotic drugs, 86  
Antithrombotic proteins, 92  
Anti-D home treatment, 364  
Aplastic anemia, 346  
Aprosalate, 242  
Aprotinin, 163, 236  
Arterial hypertension, 107  
Arterial thrombosis, 18, 94, 225, 330  
Arthroplasty, 99  
Arthroplasty, elective total hip, 241  
Aspirin, 112, 282, 285, 342  
Atherosclerosis, 42, 114, 122, 182  
Atherosclerosis of carotid, 271  
Atherosclerosis prevention, 374  
Atherosclerotic plaques, 351  
Atherothrombosis, 149  
Atherothrombotic risk, 126  
Atrial fibrillation, 108  
Autologous bone marrow transplant, 320, 361  
BMI, 102  
BMI and arterial tension, 102  
BMI and glucose, 102  
BMI and lipids, 102

Behçets Disease, 168  
 Beta thalassaemia major, 340  
 Beta2 glycoprotein I, 210  
 Beta2-GPI immunoassay, 56  
 Beta2-Glycoprotein I, 55  
 Biological diagnosis of VTD, 89  
 Biological study of VTD, 88, 91  
 Bladder carcinoma, 301, 313  
 Blood cells, thrombosis regulatory, 73  
 Bone Marrow Transplant, 361  
 Bowel intramural haemorrhage, 368  
 B-MODE Imaging, 17  
 B-Mode method, 19

Cancer and haemostasis, 7  
 Carbon line prosthesis, 338  
 Carcinoma markers, 390  
 Cardiac disease prediction, 101  
 Cardiac valve replacement, 250  
 Cardiopulmonary bypass, 358  
 Cardiovascular disease, 182, 370, 374  
 Cardiovascular disease prevention, 100  
 Cardiovascular risk factors, 150  
 Castration, 111  
 Catheters care, 372  
 Cerebral ischaemia, 225  
 Cerebral thrombotic stroke, 16  
 Cerebro vascular stroke, 344  
 Cerebrovascular disease, 96  
 Cerebrovascular ischaemia, 109  
 Chemotherapy, 319, 347  
 Chemotherapy resistance, 313  
 Cholesterol, 31  
 Cholesterolemia, 374  
 Chronic lymphatic leukaemia, 318  
 Chronic microproliferative disease, 367  
 Clopidogrel, 283  
 Coagulation inhibitors, 109  
 Coagulation markers, 228  
 Coag.Factors congenital alterations, 71  
 Coenzyme in carboxylation, 369  
 Complement fixing antibodies, 181  
 Compression method, 253  
 Consensus in OAC therapy, 85  
 Consensus in antiplatelet therapy, 84  
 Coronary bypass, 236  
 Coronary artery bypass surgery, 112  
 Coronary artery disease, 27, 173, 187, 200  
 Coronary bypass surgery, 121, 256  
 Coronary circulation, 98  
 Coronary heart disease, 342  
 Coronary reocclusion, 355  
 Coronary thromboembolism, 355  
 Cost effectiveness of prophylaxis, 378  
 Coumarin, 316  
 Coumarin derivatives, 274  
 Coumarin drugs, 288  
 Crioprecipitate treatment, 329  
 Critical limb ischaemia, 6, 50  
 Cushing's syndrome, 205  
 Cyclohexamide, 356  
 Cytokine receptor, 359  
 Cytokines, 319

DUCCS trial, 11  
 DVP and haemorrhology, 341  
 DVT, 14, 43, 44, 45, 46, 47, 104  
 DVT and ACA, 138  
 DVT and F. 1+2, 201  
 DVT and HO, 249  
 DVT and age, 270  
 DVT and knee replacement, 235  
 DVT and thrombomodulin, 204  
 DVT and upper limb DVT, 234  
 DVT diagnosis, 21, 201  
 DVT in pregnant woman, 47  
 DVT postoperative, 222, 237  
 DVT prevention, 209, 239  
 DVT profilaxis, 381  
 DVT proximal, 238  
 DVT, femoral, 135  
 DVT, iliofemoral, 253  
 Dalteparin, 43, 45, 46, 47  
 Descarboxyprothrombin as marker, 390  
 Desmopresin, 325  
 Dextrane, 40, 229, 386  
 Diabetes, 60, 271, 286, 353  
 Diabetes mellitus type II, 348  
 Diabetes, non-insulin dependant, 177  
 Diabetic patients, 130  
 Diabetic retinopathy, 349  
 Diagnostic methods, 51  
 Dietary intakes in children, 118  
 Digoxigenin, 302  
 Drugs anticoagulant effect, 24  
 Duplex scanner color method, 17  
 Dural sinus thrombosis, 16  
 Dysfibrinogenemias, 147, 326  
 Dysfibrinogenemia, familial, 202  
 D-Dimer and TAT, 300  
 D-Dimer and venous occlusion, 180  
 D-Dimer as marker, 197

ECSG-6 trial, 11  
 EDRF and platelet activation, 183  
 EMERAS trial, 1  
 ET and smoking, 128  
 Bowel intramural haemorrhage, 368  
 B-MODE Imaging, 17  
 B-Mode method, 19

Cancer and haemostasis, 7  
 Carbon line prosthesis, 338  
 Carcinoma markers, 390  
 Cardiac disease prediction, 101  
 Cardiac valve replacement, 250  
 Cardiopulmonary bypass, 358  
 Cardiovascular disease, 182, 370, 374  
 Cardiovascular disease prevention, 100  
 Cardiovascular risk factors, 150  
 Castration, 111  
 Catheters care, 372  
 Cerebral ischaemia, 225  
 Cerebral thrombotic stroke, 16  
 Cerebro vascular stroke, 344  
 Cerebrovascular disease, 96  
 Cerebrovascular ischaemia, 109  
 Chemotherapy, 319, 347  
 Chemotherapy resistance, 313  
 Cholesterol, 31  
 Cholesterolemia, 374  
 Chronic lymphatic leukaemia, 318  
 Chronic mieloproliferative disease, 367  
 Clopidogrel, 283  
 Coagulation inhibitors, 109  
 Coagulation markers, 228  
 Coag. Factors congenital alterations, 71  
 Coenzyme in carboxylation, 369  
 Complement fixing antibodies, 181  
 Compression method, 253  
 Consensus in OAC therapy, 85  
 Consensus in antiplatelet therapy, 84  
 Coronary bypass, 236  
 Coronary artery bypass surgery, 112  
 Coronary artery disease, 27, 173, 187, 200  
 Coronary bypass surgery, 121, 256  
 Coronary circulation, 98  
 Coronary heart disease, 342  
 Coronary reocclusion, 355  
 Coronary thromboembolism, 355  
 Cost effectiveness of prophylaxis, 378  
 Coumarin, 316  
 Coumarin derivatives, 274  
 Coumarin drugs, 288  
 Crioprecipitate treatment, 329  
 Critical Limb ischaemia, 50  
 Critical limb ischaemia, 6  
 Cushing's syndrome, 205  
 Cyclohexamide, 356  
 Cytokine receptor, 359  
 Cytokines, 319  
 DUCCS trial, 11  
 DVP and haemorrhology, 341  
 DVT, 14, 43, 44, 45, 46, 47, 104  
 DVT and ACA, 138  
 DVT and F, 1+2, 201  
 DVT and HO, 249  
 DVT and age, 270  
 DVT and knee replacement, 235  
 DVT and thrombomodulin, 204  
 DVT and upper limb DVT, 234  
 DVT diagnosis, 21, 201  
 DVT in pregnant woman, 47  
 DVT postoperative, 222, 237  
 DVT prevention, 209, 239  
 DVT profilaxis, 381  
 DVT proximal, 238  
 DVT, femoral, 135  
 DVT, iliofemoral, 253  
 Dalteparin, 43, 45, 46, 47  
 Descarboxyprothrombin as marker, 390  
 Desmopresin, 325  
 Dextran, 229  
 Dextrane, 40, 386  
 Diabetes, 60, 271, 286, 353  
 Diabetes mellitus type II, 348  
 Diabetes, non-insulin dependant, 177  
 Diabetic patients, 130  
 Diabetic retinopathy, 349  
 Diagnostic methods, 51  
 Dietary intakes in children, 118  
 Digoxigenin, 302  
 Drugs anticoagulant effect, 24  
 Duplex scanner color method, 17  
 Dural sinus thrombosis, 16  
 Dysfibrinogenemia, 326  
 Dysfibrinogenemias, 147  
 Dysfibrinogenemia, familial, 202  
 D-Dimer and TAT, 300  
 D-Dimer and venous occlusion, 180  
 D-Dimer as marker, 197  
  
 ECSG-6 trial, 11  
 EDRF and platelet activation, 183  
 EMERAS trial, 1  
 ET and smoking, 128  
 EXNER test, 156  
 Echocardiography, 15  
 Eicosanoids and thrombin, 191  
 Elderly people and D-Dimer, 110  
 Elderly people and F 1 +, 2, 110  
 Endothelial cells, 72, 151  
 Endothelial tissue factor, 186  
 Enoxaparin, 232  
 Enoxaparin and dialysis, 281  
 Epidemiology, 28, 29, 58, 376, 53  
 Epidemiology, arterial thrombosis, 2, 5  
 Epidemiology, venous thrombosis, 25  
 Epidural anaesthesia, 235

Erythrocyte flexibility, 349  
 Erythrocytapheresis, 347  
 Erythrocyte membrane, 124  
 Erythrocyte membrane in aging, 127  
 Erythrocyte rigidity, 349  
 European Multicentre trial, 44  
 Experimental thrombosis, 247  
 Extracranial arteries disease, 17  
 Extrinsic pathway of coagulation, 356  
  
 F I+2 and DVT, 201  
 F I+2 and protein C, 222  
 F I+2 in Pulmonary embolism, 220  
 FPE, 104  
 FTT trial, 1  
 FVIIIa-novel chromogenic assay, 219  
 Factor V anticoagulant properties, 9  
 Factor V as cofactor to APC, 9  
 Factor VII activation, 245  
 Factor VII and renal transplant, 196  
 Factor VII in sepsis, 308  
 Factor VIII concentrate treatment, 329  
 Factor VIII concentrates, 363  
 Factor VIII in ABMT, 320  
 Factor VIII in sepsis, 309  
 Factor VIIa activation, 358  
 Factor VIIa binding site, 359  
 Factor X activation, 343  
 Factor XI deficiency, 3  
 Factor XII Valencia, 362  
 Factor XII activation, 358  
 Factor XII activity, 362  
 Factor XII antigen, 362  
 Factor XII inhibitor, 362  
 Factor XIII and diabetes, 130  
 Factor von Willebrand in sepsis, 308  
 Felopidine, 231  
 Femoropopliteal graft occlusion, 352  
 Fibrin deposition in peritonitis, 166  
 Fibrinogen, 95, 366  
 Fibrinogen Barcelona III, 147  
 Fibrinogen Barcelona IV, 147  
 Fibrinogen San Sebastian, 326  
 Fibrinogen Villajoyosa, 1, 147  
 Fibrinogen and atherosclerosis, 106  
 Fibrinogen and diabetic platelets, 159  
 Fibrinogen and diabetes mellitus, 132, 160  
 Fibrinogen endocytosis, 365  
 Fibrinogen in blood, 106  
 Fibrinolysis and ALL, 265  
 Fibrinolysis and diabetes, 177, 199  
 Fibrinolysis and exercise, 169  
 Fibrinolysis and interleukin, 176  
 Fibrinolysis and long travel, 227  
 Fibrinolysis and pregnancy, 303

Fibrinolysis and sepsis, 170, 171  
 Fibrinolysis and vasodilatation, 174  
 Fibrinolysis and venous thrombosis, 162  
 Fibrinolysis in renal diseases, 179  
 Fibrinolysis in youth, 199  
 Fibrinolysis markers, 228  
 Fibrinolysis treatment, 392  
 Fibrinolytic agents, 178  
 Fibrinolytic function, 90  
 Fibrinolytic system, 38, 68, 154  
 Fibrinolytic therapy, 13, 167  
 Fibrinolytic treatment, 380  
 Fibrinopeptide A and AMI, 217  
 Foetal development, 68  
 Food habits, 374  
 Fragment I+2, 352, 355, 358, 360  
 Fragment I+2 in pregnant women, 323  
 Fragment F I+2, 125  
 Fraximin, 44, 229  
 Fraxiparine and DVT, 240  
 Fraxiparine and MI, 240  
 Fraxiparine and PE, 240  
 Fraxiparine and PF4, 189  
  
 GPIIb/IIIa, 325  
 GPIIb/IIIa complex, 321  
 GUSTO trial, 1  
 Gabexate mesilate, 250  
 Genetic counseling in haemophilia, 388  
 Glanzmann thrombasthenia, 3  
 Glycoprotein IIB-IIIa, 365  
 Glycoprotein IIB/IIIa, 367  
 Glycoprotein IIIa, 3  
 Growth factors, 113  
 Gynecologic malignancies, 316  
  
 HART study, 11  
 HAT, 148  
 HELLP syndrome diagnosis, 69  
 HELLP syndrome management, 69  
 HIV negative haemophiliacs, 329, 363  
 HMWH, pharmacokinetics, 273  
 Haemodialysis, 281  
 Haemorrhological alterations, 61  
 Haemorrhology, 58, 59, 60  
 Haemorrhology in polycythemia vera, 347  
 Haemorrhology treatment, 63  
 Haemostasis and long travel, 227  
 Hemovasal, 257  
 Heparan sulfate proteoglycan, 200  
 Heparin, 6, 11, 14, 23, 36, 43, 46, 189, 237, 358  
 Heparin and vascular surgery, 48  
 Heparin continuous infusion, 44  
 Heparin in horses red blood cells, 278  
 Heparin in surgery, 276

Heparin once daily administration, 44  
 Heparin release under stress, 195  
 Heparin binding significance, 262  
 Heparin-like components, 287  
 Heparin, unfractionated, 246, 252, 260, 270  
 Heparin, unfractionated in rat model, 275  
 Hepatocellular carcinoma, 390  
 Heterotopic ossification (HO), 249  
 Hip arthroplasty, 241, 382  
 Hip fractures and coagulation, 136  
 Hip replacement in pigs, 135  
 Hip replacement, total, 377  
 Hip surgery, 20, 23, 233, 237  
 Hip surgery (elective) and DVT, 229  
 Hirudin, 83, 252, 263  
 Hirudin and APTT, 263  
 Homocysteine, 96  
 Hormonal replacement therapy, 38  
 Hyperbaric exposure and haemostasis, 208  
 Hyperbaric stress, 208  
 Hypercholesterolemia, 107  
 Hypercholesterolemia, diet-induced, 113  
 Hypercoagulability and TEG, 203  
 Hypercoagulability in obesity, 39  
 Hypercoagulability, 207  
 Hypercoagulation state, 340  
 Hyperfibrinolytic state, 360  
 Hyperlipoproteinemia, 58  
 Hypertension, 40, 149, 150  
 Hypertension essential, 207, 231  
 Hypertension in aging, 126  
 Hyperviscosity, 349  
 Hypofibrinolysis diagnosis, 162  
 Hypofibrinolysis prevalence, 304  
 Hypofibrinolysis and abortion, 304  
 Hypofibrinolysis in Behçet's, 168  
 Hysterectomy, abdominal, 111  
  
 ICU thromboembolism prevention, 393  
 IPLC in hip surgery, 237  
 ITP, 364  
 Idiopathic thrombocytopenic purpura, 336  
 Immune thrombocytopenic purpura, 364  
 Immunochrom APC-FVIII, 219  
 Immunothrombocytopenia, 70  
 Inandionic rodenticide, 369  
 Indobufen and platelets, 280  
 Inferior vena cava filter thrombi, 289  
 Inferior vena cava thrombosis, 13  
 Inflammation, 181  
 Inflammatory mediators, 8  
 Insulin resistance, 37  
 Interferon gamma, 319  
 Interleukin, 6, 360  
 Interleukin and fibrinolysis, 176  
  
 Interleukin-10, 306  
 Intron 40 vWillebrand factor, 324  
 Intraplatelet fibrinogen, 366  
 Intrauterine therapy, 71  
 Intravenous heparin, 43  
 Ischaemia, silent, 117  
 Ischaemic heart disease, 185  
 Ischaemic stroke, 351  
 Ischaemic pathology, 61  
  
 Knee prosthesis, 382  
 Konakion, 369  
  
 LA and APTT, 226  
 LA diagnosis, 156, 335  
 LA in youth, 137  
 LATE trial, 1  
 LMWH, 5, 22, 120, 229, 233, 241, 244, 245, 246, 247, 253, 259, 261, 270, 317, 330, 386, 393  
 LMWH and DVT, 248  
 LMWH and UFH, 253  
 LMWH in THA, 99  
 LMWH in gynecologic malignancies, 316  
 LMWH in hip surgery, 22, 378  
 LMWH in horses red blood cells, 278  
 LMWH in surgery patients, 267  
 LMWH pharmacokinetic profile, 258  
 LMWH treatment in CLL, 318  
 LMWHM, 36  
 LP(a) and obesity, 223  
 LP(a) and thrombosis, 223  
 Leukotriene E4, 185  
 Limb ischaemia, 49, 50  
 Lipid peroxidation, 124  
 Lipid profile in children, 119  
 Lipids, 118  
 Lipids and haemostasis, 115  
 Lipoprotein(a), 98, 125  
 Liver cirrhosis, 165  
 Liver cirrhosis, TAT and PAP, 211  
 Liver disease, 360  
 Liver function markers, 211  
 Lower extremities thrombosis, 18  
 Lp(a) and diabetes, 130  
 Lp(a) as marker diabetes mellitus, 133  
 Lp(a) in COPD, 182  
 Lupus anticoagulant, 51  
 Lymphocyte stimulation, 329  
  
 MDA in aortic artery, 184  
 MDA in portal vein, 184  
 Magnetic resonance Imaging method, 16  
 Malignancy thromboembolism, 34  
 Mannitol's effect in MDA, 184  
 Marker for leukemia, 310

Markers of coagulation, 212  
 Markers of endothelial damage, 216  
 Markers, biological, 376  
 Membrane lipid asymmetry, 54  
 Menopausal women, 370  
 Menopause, 38  
 Metabolic risk factors, 41  
 Method ultrasound imaging, 21  
 Methods: B-mode ultrasonography, 235  
 Methods: Color Doppling, 234  
 Methods: Doppler ultrasound, 234  
 Methods: FVIIIa chromogenic assay, 219  
 Methods: Magnetic Resonance Imaging 167  
 Methods: PCR, 3  
 Methods: flow cytometry, 186, 188  
 Methods: immunocytochemical, 187  
 Methods: nephelometry, 129  
 Methods: thromboelastograph, 246  
 Methods: ultrasound Doppler, 19  
 Microangiopathy functional assess, 62  
 Mieloproliferative disorders, 311  
 Miocardial infarction, 342  
 Molecular defect in Factor Va, 93  
 Molecular genetics of Factor XI, 3  
 Monocytes, 356  
 Mopidamol, 272  
 Multicenter trial, 43, 44

Navelbine, 313  
 Neonatology, 70  
 Nephropathy, 353  
 Neutropenia, 314  
 Nicotinamide, 317  
 Non invasive methods, 16, 18, 238, 239  
 Non-invasive methods and DVT, 234  
 Nurses and research, 385  
 Nurses in carrier diagnosis, 388  
 Nurses responsibility in operation, 383  
 Nursing and OAT monitoring, 389

OAC, 233  
 OAT, 152, 368  
 OAT after MI, 345  
 OAT cost, effectiveness, 345  
 OSIRIS study, 11  
 Obesity, 39, 374  
 Obesity and haemostasis parameters, 114  
 Oral anticoagulant therapy, 81  
 Oral anticoagulant treatment, 85  
 Oral contraceptives and APC resist, 144  
 Orthopaedic surgery, 379  
 Orthotopic liver transplant, 163  
 Osteoarticular lesions, 381  
 Osteoporosis, 46

Ovarian cancer, 300  
 Oxidizing agents and aging, 127

PAI activity, 94  
 PAI antigenicity, 94  
 PAI1, 8, 302, 360  
 PAI1 and restenosis after PTCA, 209  
 PAI1 in PTCA, 224  
 PAI1 in platelet concentrates, 391  
 PAI1 in polycythemia, 312  
 PAI1 in thrombocytopenia, 312  
 PDGF--BB, 113  
 PE, 104  
 PE in mice, 260  
 PEG-hirudin, 260  
 PEG-hirudin and PE in mice, 260  
 POAD, 6  
 POAD and fibrinolysis, 177  
 PPA and cardiopulmonary bypass, 206  
 PTCA, 2, 98  
 PUFA ethyl ester treatment, 134  
 Paraplegic patients, 33  
 Peripheral arterial disease, 352  
 Peripheral embolism, 351  
 Peripheral obliterative disease, 6  
 Peripheral occlusive disease, 28, 392  
 Peripheral vascular disease, 353  
 Peripheral venous thrombosis, 266  
 Peritoneal mast cells, 193  
 Peritonitis and fibrinolysis, 165  
 Phlebography, 379, 380  
 Phospholipase C, 356  
 Phospholipid antibodies, 52  
 Phospholipid cofactors, 56  
 Picotamide, 271, 348  
 Placenta tissue, 302  
 Placental Function, 68  
 Plasminogen activator, 357  
 Plasmapheresis, 346  
 Plasmin, 343, 355  
 Plasmin induced activation, 356  
 Plasminogen activator inhibitor, 41  
 Plasmin-induced activation, 174  
 Platelet activation, 181, 192, 198, 339  
 Platelet activation and EDRF, 183  
 Platelet activation markers, 97  
 Platelet aggregation, 242, 252, 321  
 Platelet alfa granules, 365  
 Platelet alteration and aging, 42  
 Platelet function, 134, 325  
 Platelet high shear filter, 339  
 Platelet hyperaggregation, 148, 367  
 Platelet in mieloproliferative disease, 311  
 Platelet procoagulant activity, 206  
 Platelet reactivity, 113

Platelet survival, 334, 340  
 Platelets, 283, 366  
 Platelets and PAI1, 391  
 Platelets congenital alterations, 71  
 Pletysmography, 379  
 Pneumatic leg compression, 237  
 Porcine model, 113  
 Postsurgical thromboembolic disease, 120  
 Post-thrombotic syndrome, 158  
 Pregnant women and APA, 323  
 Prenatal diagnosis, 3  
 Prethrombotic state in elderly, 110  
 Prevention of RFC, 116  
 Prevention of thromboembolism, 32, 33, 34, 36  
 Primary APA syndrome, 331  
 Primary billiary cyrrhosis, 131  
 Primary prophylaxis, 377  
 Prophylaxis, 316, 379  
 Prophylaxis in high risk patients, 377  
 Prophylaxis with heparin in surgery, 276  
 Prostacyclin, 184  
 Prostaglandins, 185  
 Protein C and sepsis, 164  
 Protein C deficiency, hereditary, 140  
 Protein C in ABMT, 320  
 Protein C in sepsis, 309  
 Protein S deficiency, 318  
 Protein S deficiency, acquired, 307  
 Protein S in sepsis, 309  
 Protein S inhibitor, 318  
 Proteins, antithrombotic, 92  
 Prothrombin activation, 5  
 Prothrombotic state, 205  
 Prothrombotic state markers, 153  
 RBC aggregability, 340  
 RBC aggregation, 346  
 RBC deformability, 346  
 Raynaud's phenomenon, 97  
 Recombinant hirudins, 83  
 Recombinant reagents, OAC therapy, 81  
 Recombinant thrombolytic agents, 82  
 Red cell membrane alterations, 42  
 rhGM-CSF, 361  
 Renal transplant and haemostasis, 197  
 Restenosis after PTCA, 209  
 Risk factors, 41, 94, 100, 371, 381  
 Risk factors in elderly people, 375  
 Risk factors: CRF, 107  
 Risk factors: POAD, 6  
 Risk factors: aging, 126  
 Risk factors: diganosis in vascular, 116  
 Risk factors: hyperlipemia, 131  
 Risk factors: hypertension, 149  
 Risk factors: in youth, 103  
 Risk factors: metabolic, 114  
 Risk factors: oophorectomy, 111  
 Risk factors: silent ischaemia, 117  
 Risk factors: thrombophilia, 103  
 SIRS, 8  
 STACLOT LA test, 156  
 STACLOT PNP test, 156  
 Secondary prevention, 342  
 Sepsis, 8, 194, 210, 308, 309, 372  
 Sepsis and TRG, 203  
 Septic shock, 306, 308, 309, 314  
 Sialic acid, 340  
 Silent infarction prevalence, 117  
 Skin capillary fragility, 349  
 Smoking, 128, 216  
 Smoking and hypertension, 150  
 Smooth muscle cell proliferation, 350  
 Smooth muscle cells, 151  
 Sneddon's syndrome, 331, 332  
 Social stress and coagulation, 221  
 Stable angina, 342  
 Staclot LA test, 335  
 Standardization of APTT, 87  
 Streptokinase, 266  
 Stroke risk factors, 26  
 Subcutaneous heparin, 43  
 scu-PA, 357  
 Sulodexide in chronic heart failure, 279  
 Superwarfarins, 369  
 Surgical castration, 111  
 Swedish multicenter trial, 43  
 Systemic lupus erythematosus, 218  
 T4 cells, 363  
 T4-T8 ratio, 329, 363  
 TAMI trial, 11  
 TAT, 300, 355, 360  
 TAT and stress in rats, 221  
 TAT in PTCA, 224  
 TAT in pulmonary embolism, 220  
 TFI, 153  
 TFPI, 5, 247, 255  
 TFPI and LMWH, 251  
 TFPI and cardiopulmonary bypass, 153  
 TFPI as marker of IBD, 155  
 TFPI as markers, 194  
 TFPI in inflammatory bowel, 155  
 TFPI modulation, 65  
 TGF-beta1, 113  
 THA, 99  
 THA and mortality, 99  
 THP and control of blood loss, 386  
 t-PA, 360

t-PA and coronary disease, 173  
t-PA and exercise, 169  
t-PA and monoclonal antibodies, 178  
t-PA and venous occlusion, 180  
t-PA in platelet concentrates, 391  
t-Pa and bladder carcinoma, 301  
TRAP-6, 192  
Thrombin, 191, 193  
Thrombin activity, 352  
Thrombin and PTCA, 2  
Thrombin and arterial injury, 2  
Thrombin generation, 355  
Thrombin in arterial thrombosis, 2  
Thrombin inhibition, 242  
Thrombin inhibitor, 269, 275  
Thrombin inhibitors, 2  
Thrombin potential, 24  
Thrombin receptor, 350  
Thrombin receptors, 192  
Thrombin, mitogen for vascular cell, 2  
Thrombocythemia, essential, 315  
Thrombocytopenia, 148, 314, 333, 334  
Thrombocytopenia, essential, 367  
Thrombocytopenia, essential (EP), 128  
Thrombocytopenia, immune, 181  
Thrombocytosis, 315  
Thromboelastography, 259  
Thromboembolic prophylaxis, 371  
Thromboembolism in AMI, 32  
Thrombolysis, 11, 356, 357  
Thrombolysis in AMI, 1, 10, 12  
Thrombolysis resolved uncertainties, 1  
Thrombolytic strategies, 1  
Thrombolytic treatment, 266  
Thrombomodulin, 216  
Thrombomodulin and liver cirrhosis, 165  
Thrombomodulin as marker of DVT, 204  
Thrombophilia, 92  
Thrombophilia and APC, 157  
Thrombophilia hereditary, 330  
Thrombophilia markers, 133, 354  
Thrombophilia state predictors, 223  
Thrombophilia, familial, 202  
Thrombophilia, inherited, 213  
Thrombophilia: inherited, 103  
Thromboprophylaxis, 104  
Thromboregulation, 72  
Thrombosis, 58  
Thrombosis and diabetes, 286  
Thrombosis and oral contraceptives, 305  
Thrombosis in dural sinus, 16  
Thrombosis prevalence, 305  
Thrombosis recurrent, 356  
Thrombosis - inferior vena cava, 13  
Thrombotic disease, 90  
Thrombotic diseases in youth, 30  
Thromboxane, 185  
Thromboxane, 2 urinary excretion, 340  
Thromboxane in diabetes mellitus, 348  
Ticlopidine, 331, 342, 353  
Tissue Factor antigen in plasma, 67  
Tissue factor, 190, 356, 359  
Tissue factor activation, 358  
Tissue factor and sepsis, 66  
Tissue factor as marker, 194  
Tissue factor function, 64  
Tissue factor in bladder carcinoma, 313  
Tissue factor in leukemic cells, 310  
Tissue factor induced coagulation, 65  
Tissue factor structure, 64  
Tissue factors modulators, 313  
Tissue type plasminogen activator, 41  
Transesophageal Echocardiography, 15  
Transesophageal echocardiography, 230, 288, 351  
Triflusal, 282  
Tumor necrosis factor, 319, 360  
Ultrasound Doppler method, 19  
Ultrasound imaging method, 21  
Unstable angina, 345  
Urokinase, 14, 266, 392  
Urokinase receptor, 172  
VTD, 4, 104, 376, 382  
Valves, Leiden artificial, 243  
Vascular brain disease, 105  
Vascular restenosis, 350  
Vasopressin analog (DGAVP), 123  
Vein graft occlusion, 236, 256  
Vein graft patency, 112, 121  
Venous thromboembolic disease, 88, 89, 268  
Venous thromboembolism, 254  
Venous thromboembolism prevention, 232, 233  
Venous thrombosis, 18, 330  
Venous thrombosis and PAF, 145  
Venous thrombosis disease, 91  
Venous thrombosis in rat, 145  
Venous thrombosis, recurrent, 318  
Venous thromboembolism, hip surgery, 20  
Von Willebrand disease, acquired, 337  
Von Willebrand disease, type IIB, 327, 328  
Von Willebrand factor, 339, 352  
Warfarin, 45, 112, 232